Literature DB >> 23124598

Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.

George Pentheroudakis1, Yael Spector, Dimitrios Krikelis, Vassiliki Kotoula, Eti Meiri, Vassiliki Malamou-Mitsi, George Fountzilas, Mats Sanden, Nicholas Pavlidis, Hila Benjamin, Ranit Aharonov.   

Abstract

No data exist on biologic differences between Cancer of unknown primary (CUP) and metastatic solid tumors of known primary site. We assigned a primary tissue of origin in 40 favorable CUP patients (A: serous peritoneal carcinomatosis n = 14, B: axillary adenocarcinoma n = 8, C: upper squamous cervical adenopathy n = 18) by means of a 64-microRNA assay. Subsequently, we profiled the expression of 733 microRNAs (miRs) in the CUP cases and compared results with metastases from 20 ovarian carcinomas, 10 breast adenocarcinomas, 20 squamous head neck or lung tumors. In the Peritoneal CUP versus Ovarian (Known Primary Metastases) KPM comparison, a total of 12 miR were significantly differentially expressed: higher than twofold expression difference in CUP was seen only for miR-513a-5p (3.7-fold upregulated) and miR-483-5p (2.5-fold upregulated), while miR-708 exhibited a twofold downregulation. In the Breast CUP versus Breast KPM comparison, only miR-29c that were downregulated in CUP by 2.7-fold satisfied the FDR threshold. miR-30e and miR-27b, downregulated in ovarian CUPs versus KPMs, were also non-significantly downregulated in breast CUP by 2.0- and 1.4-fold respectively. Six miRs, which belong to the 17-92 oncocluster showed a trend of upregulation in Breast CUP versus Breast KPM cases. A CUP signature remains elusive.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124598     DOI: 10.1007/s10585-012-9548-3

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  36 in total

1.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

2.  Complexity of the microRNA repertoire revealed by next-generation sequencing.

Authors:  Lik Wee Lee; Shile Zhang; Alton Etheridge; Li Ma; Dan Martin; David Galas; Kai Wang
Journal:  RNA       Date:  2010-09-28       Impact factor: 4.942

3.  miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities.

Authors:  M Mraz; K Malinova; J Kotaskova; S Pavlova; B Tichy; J Malcikova; K Stano Kozubik; J Smardova; Y Brychtova; M Doubek; M Trbusek; J Mayer; S Pospisilova
Journal:  Leukemia       Date:  2009-01-22       Impact factor: 11.528

4.  The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Authors:  Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; M Catherine Lee; Loretta Loftus; Hatem Soliman; Judy C Boughey; Carol Reynolds; Thomas J Lawton; Peter I Acs; Lucio Gordan; Geza Acs
Journal:  Oncologist       Date:  2011-10-20

5.  Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.

Authors:  Gauri R Varadhachary; Yael Spector; James L Abbruzzese; Shai Rosenwald; Huamin Wang; Ranit Aharonov; Heather R Carlson; Dalia Cohen; Siddharth Karanth; Joanna Macinskas; Renato Lenzi; Ayelet Chajut; Tina B Edmonston; Martin N Raber
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

6.  A second-generation microRNA-based assay for diagnosing tumor tissue origin.

Authors:  Eti Meiri; Wolf C Mueller; Shai Rosenwald; Merav Zepeniuk; Elizabeth Klinke; Tina Bocker Edmonston; Margot Werner; Ulrike Lass; Iris Barshack; Meora Feinmesser; Monica Huszar; Franz Fogt; Karin Ashkenazi; Mats Sanden; Eran Goren; Nir Dromi; Orit Zion; Ilanit Burnstein; Ayelet Chajut; Yael Spector; Ranit Aharonov
Journal:  Oncologist       Date:  2012-05-22

7.  miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells.

Authors:  Sivasubramani Thulasingam; Chandirasegaran Massilamany; Arunakumar Gangaplara; Hongjiu Dai; Shahlo Yarbaeva; Sakthivel Subramaniam; Jean-Jack Riethoven; James Eudy; Marjorie Lou; Jay Reddy
Journal:  Mol Cell Biochem       Date:  2011-02-25       Impact factor: 3.396

Review 8.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

Review 9.  Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin.

Authors:  Federico A Monzon; Tracie J Koen
Journal:  Arch Pathol Lab Med       Date:  2010-02       Impact factor: 5.534

Review 10.  Cancer of unknown primary site: missing primary or missing biology?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Nicholas Pavlidis
Journal:  Oncologist       Date:  2007-04
View more
  10 in total

Review 1.  Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Authors:  John D Hainsworth; F Anthony Greco
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

2.  Umbilical Nodule Metastasis from Unknown Primary: Diagnostic and Therapeutic Dilemma.

Authors:  Sweety Gupta; Gaurav Sharma; Nidhi Sharma; Shreyosi Mandal; Amit Gupta; Manoj Gupta
Journal:  Surg J (N Y)       Date:  2022-06-30

3.  Increased copy number of the DLX4 homeobox gene in breast axillary lymph node metastasis.

Authors:  Clarissa Torresan; Márcia M C Oliveira; Silma R F Pereira; Enilze M S F Ribeiro; Catalin Marian; Yuriy Gusev; Rubens S Lima; Cicero A Urban; Patricia E Berg; Bassem R Haddad; Iglenir J Cavalli; Luciane R Cavalli
Journal:  Cancer Genet       Date:  2014-05-02

4.  Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells.

Authors:  Anna Komina; Nadezhda Palkina; Mariya Aksenenko; Seseg Tsyrenzhapova; Tatiana Ruksha
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

Review 5.  Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.

Authors:  Alicia-Marie Conway; Claire Mitchell; Elaine Kilgour; Gerard Brady; Caroline Dive; Natalie Cook
Journal:  Br J Cancer       Date:  2018-12-23       Impact factor: 7.640

Review 6.  Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease?

Authors:  Alaa T Alshareeda; Batla S Al-Sowayan; Reem R Alkharji; Sahar M Aldosari; Abdullah M Al Subayyil; Ayidah Alghuwainem
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

Review 7.  Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered.

Authors:  Elie Rassy; Tarek Assi; Stergios Boussios; Joseph Kattan; Julie Smith-Gagen; Nicholas Pavlidis
Journal:  Ann Transl Med       Date:  2020-12

Review 8.  A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists.

Authors:  Nicholas Pavlidis; Hussein Khaled; Rabab Gaafar
Journal:  J Adv Res       Date:  2014-11-21       Impact factor: 10.479

Review 9.  Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era.

Authors:  Francisco J Civantos; Jan B Vermorken; Jatin P Shah; Alessandra Rinaldo; Carlos Suárez; Luiz P Kowalski; Juan P Rodrigo; Kerry Olsen; Primoz Strojan; Antti A Mäkitie; Robert P Takes; Remco de Bree; June Corry; Vinidh Paleri; Ashok R Shaha; Dana M Hartl; William Mendenhall; Cesare Piazza; Michael Hinni; K Thomas Robbins; Ng Wai Tong; Alvaro Sanabria; Andres Coca-Pelaz; Johannes A Langendijk; Juan Hernandez-Prera; Alfio Ferlito
Journal:  Front Oncol       Date:  2020-11-10       Impact factor: 6.244

10.  MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.

Authors:  Noemi Laprovitera; Mattia Riefolo; Elisa Porcellini; Giorgio Durante; Ingrid Garajova; Francesco Vasuri; Ariane Aigelsreiter; Nadia Dandachi; Giuseppe Benvenuto; Federico Agostinis; Silvia Sabbioni; Ioana Berindan Neagoe; Chiara Romualdi; Andrea Ardizzoni; Davide Trerè; Martin Pichler; Antonietta D'Errico; Manuela Ferracin
Journal:  Mol Oncol       Date:  2021-06-23       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.